drugset / Trial / NCT02273544

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

NCT02273544

Phase 1 Terminated 16 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this study was to compare the pharmacokinetics of dipyridamole in three different Asasantin ER batches (test) containing different amounts of retarding lacquers to the existing commercial product at steady state with b.i.d. treatment

Timeline

Start
2002-09
Primary completion
2002-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dipyridamole Other / unclassified 200 mg
Background Aspirin Small molecule 25 mg

Indications

No indication recorded.